Genetics and epigenetics of primary Sjögren syndrome: implications for future therapies

GE Thorlacius, A Björk… - Nature Reviews …, 2023 - nature.com
In primary Sjögren syndrome (pSS), chronic inflammation of exocrine glands results in tissue
destruction and sicca symptoms, primarily of the mouth and eyes. Fatigue, arthralgia and …

Current and future therapies for primary Sjögren syndrome

R Seror, G Nocturne, X Mariette - Nature Reviews Rheumatology, 2021 - nature.com
Primary Sjögren syndrome (pSS) is a systemic autoimmune disease that is characterized by
a triad of symptoms that affect all patients (dryness, pain and fatigue). In addition, systemic …

Update on the pathophysiology and treatment of primary Sjögren syndrome

C Baldini, G Fulvio, G La Rocca, F Ferro - Nature Reviews …, 2024 - nature.com
Sjögren syndrome or Sjögren disease is a chronic form of autoimmune epithelitis
characterized by lymphocytic infiltration of the exocrine glands, particularly the salivary and …

[HTML][HTML] A randomized, phase II study of sequential belimumab and rituximab in primary Sjögren's syndrome

X Mariette, F Barone, C Baldini, H Bootsma, KL Clark… - JCI insight, 2022 - ncbi.nlm.nih.gov
BACKGROUND Primary Sjögren's syndrome (pSS) is characterized by B cell hyperactivity
and elevated B-lymphocyte stimulator (BLyS). Anti-BLyS treatment (eg, belimumab) …

Composite of Relevant Endpoints for Sjögren's Syndrome (CRESS): development and validation of a novel outcome measure

S Arends, L de Wolff, JF van Nimwegen… - The Lancet …, 2021 - thelancet.com
Background Recent randomised controlled trials (RCTs) in primary Sjögren's syndrome
used the European League Against Rheumatism (EULAR) Sjögren's Syndrome Disease …

CD8+ T Lymphocytes: Crucial Players in Sjögren's Syndrome

H Zhou, J Yang, J Tian, S Wang - Frontiers in immunology, 2021 - frontiersin.org
Primary Sjögren's syndrome (pSS) is a chronic autoimmune disease associated with
damage to multiple organs and glands. The most common clinical manifestations are dry …

Biological therapy in systemic lupus erythematosus, antiphospholipid syndrome, and Sjögren's syndrome: evidence-and practice-based guidance

A Marinho, J Delgado Alves, J Fortuna, R Faria… - Frontiers in …, 2023 - frontiersin.org
Systemic lupus erythematosus (SLE), antiphospholipid syndrome (APS), and Sjögren's
syndrome (SS) are heterogeneous autoimmune diseases. Severe manifestations and …

Tailoring the treatment of inflammatory rheumatic diseases by a better stratification and characterization of the clinical patient heterogeneity. Findings from a …

P Ruscitti, Y Allanore, C Baldini, G Barilaro… - Autoimmunity …, 2024 - Elsevier
Inflammatory rheumatic diseases are different pathologic conditions associated with a
deregulated immune response, codified along a spectrum of disorders, with …

The transcriptome of paired major and minor salivary gland tissue in patients with primary Sjögren's syndrome

GM Verstappen, L Gao, S Pringle, EA Haacke… - Frontiers in …, 2021 - frontiersin.org
Background While all salivary glands (SGs) can be involved in primary Sjögren's syndrome
(pSS), their respective role in pathogenesis remains unclear. Our objective was to assess …

Development and preliminary validation of the Sjögren's Tool for Assessing Response (STAR): a consensual composite score for assessing treatment effect in primary …

R Seror, G Baron, M Camus, D Cornec… - Annals of the …, 2022 - ard.bmj.com
Objective To develop a composite responder index in primary Sjögren's syndrome (pSS):
the Sjögren's Tool for Assessing Response (STAR). Methods To develop STAR, the …